The device expands Haemonetics’ Vascade portfolio of vascular closure systems with collapsible disc technology and resorbable collagen patches.
Vascade MVP XL has FDA premarket approval. The company said the Vascade systems can save time for hospital staff and help patients reach hemostasis faster. The first procedure using the device was performed at the Heart & Vascular Center at the University of Alabama Birmingham.
“With Vascade MVP XL, Haemonetics continues to expand its presence and broaden its reach in the $2.7 billion total addressable market for vascular closure solutions,” Stew Strong, president of global hospital at Haemonetics, said in a news release. “The introduction of VASCADE MVP XL underscores our commitment to innovation and improving patient care, as we enhance our range of vascular closure solutions to address increasing demand for catheter-based ablation technologies. We are enthusiastic about the initial launch of VASCADE MVP XL and anticipate a full market release later this year.”
Haemonetics’ line of Vascade devices includes the Vascade system for small-bore femoral arterial and venous closure with standard 5-6/7F procedural sheaths and the Vascade MVP system for mid-bore multi-access femoral venous closure with 6-12F procedure sheaths.
The upsized Vascade MVP XL system uses 58% more collagen and a larger disc than the Vascade MVP system, resulting in a more “robust” closure system for procedures that need 10-12F sheaths, including cryoablation and left atrial appendage closure for atrial fibrillation patients.
